BIXT (Bioxytran) Cyclically Adjusted PB Ratio: (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioxytran Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bioxytran  (OTCPK:BIXT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bioxytran Cyclically Adjusted PB Ratio Related Terms


Bioxytran Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Bioxytran's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioxytran Cyclically Adjusted PB Ratio Chart

Bioxytran Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.75 0.00 0.00 0.00 0.00

Bioxytran Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BIXT vs SPRC, ACUT, DCOY: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Bioxytran's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioxytran Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bioxytran's Cyclically Adjusted PB Ratio falls into.



Bioxytran Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bioxytran's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Bioxytran's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.039/330.2130*330.2130
=-0.039

Current CPI (Mar. 2026) = 330.2130.

Bioxytran Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.226 241.018 -0.310
201609 -0.251 241.428 -0.343
201612 -0.310 241.432 -0.424
201703 -0.447 243.801 -0.605
201706 -0.338 244.955 -0.456
201709 -0.296 246.819 -0.396
201712 0.000 246.524 0.000
201803 0.146 249.554 0.193
201806 0.146 251.989 0.191
201809 -0.001 252.439 -0.001
201812 -0.003 251.233 -0.004
201903 -0.008 254.202 -0.010
201906 -0.008 256.143 -0.010
201909 -0.014 256.759 -0.018
201912 -0.009 256.974 -0.012
202003 -0.021 258.115 -0.027
202006 -0.020 257.797 -0.026
202009 -0.022 260.280 -0.028
202012 -0.029 260.474 -0.037
202103 -0.037 264.877 -0.046
202106 -0.022 271.696 -0.027
202109 -0.026 274.310 -0.031
202112 -0.025 278.802 -0.030
202203 -0.033 287.504 -0.038
202206 -0.039 296.311 -0.043
202209 -0.016 296.808 -0.018
202212 -0.022 296.797 -0.024
202303 -0.028 301.836 -0.031
202306 -0.015 305.109 -0.016
202309 -0.010 307.789 -0.011
202312 -0.017 306.746 -0.018
202403 -0.002 312.332 -0.002
202406 -0.002 314.175 -0.002
202409 -0.014 315.301 -0.015
202412 -0.021 315.605 -0.022
202503 -0.031 319.799 -0.032
202506 -0.030 322.561 -0.031
202509 -0.033 324.800 -0.034
202512 -0.024 324.054 -0.024
202603 -0.039 330.213 -0.039

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bioxytran Business Description

Address 75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Glycovirology is a novel glycan-based platform technology. The concept involves using sugar-based drugs to block viruses. The company is developing an inventive platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.